Ticker	Volume	Price	Price Delta
DJIA	15,345.30	-9.06	-0.06%
S&P 500	1,668.12	+0.65	0.04%
Nasdaq	3,502.02	+3.05	0.09%

Ticker

Volume

Price

Price Delta

DJIA

15,345.30

-9.06

-0.06%

S&P 500

1,668.12

+0.65

0.04%

Nasdaq

3,502.02

+3.05

0.09%

Ticker	Volume	Price	Price Delta
STOXX 50	2,810.98	-7.01	-0.25%
FTSE 100	6,732.65	+9.59	0.14%
DAX	8,424.37	+26.37	0.31%

Ticker

Volume

Price

Price Delta

STOXX 50

2,810.98

-7.01

-0.25%

FTSE 100

6,732.65

+9.59

0.14%

DAX

8,424.37

+26.37

0.31%

Ticker	Volume	Price	Price Delta
Nikkei	15,360.80	+222.69	1.47%
Hang Seng	23,493.00	+410.35	1.78%
S&P/ASX 200	5,209.04	+28.26	0.55%

Ticker

Volume

Price

Price Delta

Nikkei

15,360.80

+222.69

1.47%

Hang Seng

23,493.00

+410.35

1.78%

S&P/ASX 200

5,209.04

+28.26

0.55%

J&J, Pfizer Alzheimer’s Study Will Be Presented in Early October

By Michelle Fay Cortez - 2012-06-20T17:13:42Z

Researchers will present the results of two late-stage studies on Johnson & Johnson (JNJ) and Pfizer Inc. (PFE)’s experimental drug for Alzheimer’s disease, bapineuzumab, at the American Neurological Association meeting in early October.

The findings of the two studies will be presented in Boston on Oct. 8 in a session dedicated to immune-based treatments for neurological disorders, according to the meeting program posted on the neurological association’s website. The results, if positive, could lead the companies to file for U.S. Food and Drug Administration approval of the medicine.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

More News:

Science

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.